<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.1" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
  <titleInfo>
    <title>Synthesis of 2-(3-methoxybenzoyl) cycl ohexan-1-one and exploration of their potential as antialzheimer agents through molecular docking studies</title>
  </titleInfo>
  <name type="personal">
    <namePart>Shanjievan A/l Arivazhagan</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <typeOfResource manuscript="yes">text</typeOfResource>
  <originInfo>
    <place>
      <placeTerm type="code" authority="marccountry">my</placeTerm>
    </place>
    <dateIssued encoding="marc">2025</dateIssued>
    <copyrightDate encoding="marc">2025</copyrightDate>
    <issuance>monographic</issuance>
  </originInfo>
  <language>
    <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
  </language>
  <physicalDescription>
    <extent>xvii, 77 pages : illustrations ;</extent>
  </physicalDescription>
  <abstract>Alzheimer’s disease (AD) is a progressive neurodegenerative disorder associated with  neuronal death, cognitive decline, and amyloid plaques and neurofibrillary tangles.  Treatments available today are limited to symptom management and are often  accompanied by significant side effects, highlighting the need for safer and more  effective therapeutic agents. In this study, 2-(3-methoxybenzoyl)cyclohexan-1-one was  synthesized, characterized using FTIR and NMR, and evaluated for its potential as an  anti-Alzheimer agent using molecular docking studies. The compound was made by  enamine and acylation reactions, monitored with thin-layer chromatography (TLC), and  purified with column chromatography, obtaining 0.3446 g of the product with a 14.9%  yield. NMR spectroscopy confirmed 14 distinct carbon environments, and FTIR analysis  confirmed diketone peaks at 1710.01 and 1677.84 cm⁻¹, validating the structure of the  synthesized compound. Molecular docking studies were performed using SwissDock  with the crystal structure of acetylcholinesterase (AChE, PDB ID: 4EY7). The  synthesized compound showed a binding affinity of −6.503 kcal/mol, whereas the cocrystallized ligand and FDA-approved drug brexpiprazole displayed binding affinities of  −7.261 kcal/mol and −7.962 kcal/mol, respectively. The synthesized compound had a  lower binding affinity but exhibited four hydrophobic contacts with ALA397, ALA528,  TYR382, and HIS381, and two π-stacking interactions with HIS381 and TYR382 in the  AChE active site, suggesting its potential inhibitory activity. The research conducted  demonstrates the promise of 2-(3-methoxybenzoyl)cyclohexan-1-one as a candidate AD  therapeutic and the utility of combining synthetic chemistry and computational studies to  identify and optimize novel therapeutic agents.</abstract>
  <targetAudience authority="marctarget">specialized</targetAudience>
  <note type="statement of responsibility">Shanjievan A/l Arivazhagan</note>
  <note>Faculty of Industrial Sciences and Technology</note>
  <note>Final Year Report (Bachelor of Applied Science of Industrial Chemistry) -- Universiti Malaysia Pahang Al-Sultan Abdullah - 2025</note>
  <note>Include bibliographical reference</note>
  <subject authority="lcsh">
    <name type="corporate">
      <namePart>Faculty of Industrial Sciences and Technology</namePart>
    </name>
    <topic>Dissertations</topic>
  </subject>
  <subject authority="lcsh">
    <topic>Universities and colleges</topic>
    <topic>Dissertations</topic>
  </subject>
  <subject authority="lcsh">
    <topic>Theses</topic>
    <topic>Dissertations</topic>
  </subject>
  <identifier type="isbn">THE0010485 (Local)</identifier>
  <identifier type="uri">https://umpir.ump.edu.my/id/eprint/46111</identifier>
  <location>
    <url>https://umpir.ump.edu.my/id/eprint/46111</url>
  </location>
  <recordInfo>
    <recordContentSource authority="marcorg">UMPSA</recordContentSource>
    <recordCreationDate encoding="marc">260421</recordCreationDate>
    <recordChangeDate encoding="iso8601">20260421121423.0</recordChangeDate>
    <languageOfCataloging>
      <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
    </languageOfCataloging>
  </recordInfo>
</mods>
